In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PFIZER/ALZA EXTENDED-RELEASE GLIPIZIDE (GLUCOTROL XL) MARKETING

Executive Summary

PFIZER/ALZA EXTENDED-RELEASE GLIPIZIDE (GLUCOTROL XL) MARKETING will begin "immediately" through Pfizer's Pratt Pharmaceuticals Division. Pfizer announced the approval of the anti-diabetes product on April 28 at its annum meeting, two days after FDA clearance and less than two weeks prior to the expiration of Pfizer's exclusive marketing protection for the standard-release dosage form of glipizide (Glucotrol). Worldwide sales of Glucotrol were $63.5 mil. (up 18%) in 1993.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel